ADMA Historical Cash Flow
| ADMA Stock | USD 17.70 0.93 4.99% |
Analysis of ADMA Biologics cash flow over time is an excellent tool to project ADMA Biologics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 90.8 M or Capital Expenditures of 3.4 M as it is a great indicator of ADMA Biologics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ADMA Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ADMA Biologics is a good buy for the upcoming year.
ADMA |
About ADMA Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ADMA balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ADMA's non-liquid assets can be easily converted into cash.
ADMA Biologics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from ADMA Biologics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' Free Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 90.8 M, whereas Change In Cash is projected to grow to (33.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation | 5.5M | 7.1M | 8.3M | 8.7M | Other Non Cash Items | 1.8M | 12.4M | 32.6M | 34.3M |
ADMA Biologics cash flow statement Correlations
Click cells to compare fundamentals
ADMA Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ADMA Biologics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.7K) | 29.2M | (4.8M) | 35.4M | (35.2M) | (33.4M) | |
| Free Cash Flow | (80.0M) | (114.7M) | (125.9M) | (73.4M) | 3.8M | 4.0M | |
| Begin Period Cash Flow | 26.8M | 26.8M | 55.9M | 51.1M | 86.5M | 90.8M | |
| Capital Expenditures | 3.8M | 12.7M | 13.5M | 13.9M | 5.0M | 3.4M | |
| Total Cash From Operating Activities | (76.2M) | (102.0M) | (112.4M) | (59.5M) | 8.8M | 9.2M | |
| Net Income | (48.3M) | (75.7M) | (71.6M) | (65.9M) | (28.2M) | (29.7M) | |
| Total Cash From Financing Activities | 80.0M | 143.9M | 121.0M | 108.9M | (39.0M) | (37.0M) | |
| End Period Cash Flow | 26.8M | 55.9M | 51.1M | 86.5M | 51.4M | 28.3M | |
| Change In Working Capital | (33.5M) | (33.8M) | (51.7M) | (18.3M) | (10.1M) | (10.6M) | |
| Other Cashflows From Financing Activities | 61.6M | (816.6K) | (62K) | (7.5M) | (14.0M) | (13.3M) | |
| Other Non Cash Items | 1.0M | 1.6M | 1.8M | 12.4M | 32.6M | 34.3M | |
| Depreciation | 3.3M | 3.9M | 5.5M | 7.1M | 8.3M | 8.7M | |
| Change To Inventory | (34.7M) | (28.5M) | (43.2M) | (38.6M) | (9.6M) | (10.1M) | |
| Sale Purchase Of Stock | 48.5M | 131.2M | (61.6K) | (2.9M) | (1.4M) | (1.3M) | |
| Change Receivables | (2.1M) | (9.8M) | (15.3M) | 13.1M | 11.8M | 12.4M | |
| Net Borrowings | 34.3M | 13.5M | (34.3K) | 49.0M | 56.3M | 59.1M | |
| Stock Based Compensation | 2.7M | 2.9M | 3.5M | 5.2M | 6.2M | 6.5M | |
| Total Cashflows From Investing Activities | (3.8M) | (12.7M) | (13.5M) | (13.9M) | (12.5M) | (11.9M) | |
| Cash And Cash Equivalents Changes | (2.7K) | 29.2M | (4.8M) | 35.4M | 40.7M | 42.8M | |
| Cash Flows Other Operating | (2.2M) | (709.6K) | (3.1M) | (633.4K) | (570.1K) | (598.6K) | |
| Change To Account Receivables | (2.1M) | (9.8M) | (15.3M) | 13.1M | (11.9M) | (11.3M) | |
| Change To Netincome | 2.9M | 1.8M | 3.7M | 15.3M | 17.6M | 18.5M | |
| Change To Liabilities | 3.9M | 1.9M | 9.9M | 7.8M | 9.0M | 9.5M | |
| Investments | (3.8M) | (12.7M) | (13.5M) | (13.9M) | (7.3M) | (7.7M) | |
| Change To Operating Activities | (49.4K) | 2.6M | 5.5M | 6.4M | 7.4M | 7.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.